Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    RITONAVIR AND LOPINAVIR

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Daré Bioscience Starts Ph 2 Study of DARE-HPV for High-Risk HPV
    Daré Bioscience Starts Ph 2 Study of DARE-HPV for High-Risk HPV

    18 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/18/3296547/30757/en/dar%c3%a9-bioscience-initiates-phase-2-study-of-dare-hpv-a-novel-pharmacologic-treatment-for-persistent-high-risk-hpv-infection-with-no-fda-approved-therapies.html

    GLOBENEWSWIRE
    18 May 2026
    Share Share
    Micro’s Generics Lopinavir And Ritonavir Receives Approval in US
    Micro’s Generics Lopinavir And Ritonavir Receives Approval in US

    11 Dec 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214696

    FDA
    11 Dec 2025
    Share Share
    Mylan's Generic Lopinavir and Ritonavir Receives Approval in the U.S.
    Mylan's Generic Lopinavir and Ritonavir Receives Approval in the U.S.

    07 Feb 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079074

    FDA
    07 Feb 2024
    Share Share
    Cipla, DNDi launch 4-in-1 antiretroviral treatment for young children with HIV
    Cipla, DNDi launch 4-in-1 antiretroviral treatment for young children with HIV

    14 Jun 2022

    // EXPRESS PHARMA

    https://www.expresspharma.in/cipla-dndi-launch-4-in-1-antiretroviral-treatment-for-young-children-with-hiv-in-south-africa/

    EXPRESS PHARMA
    14 Jun 2022
    Share Share
    Laurus' Generic Lopinavir & Ritonavir Receives Approval in the U.S.
    Laurus' Generic Lopinavir & Ritonavir Receives Approval in the U.S.

    21 Mar 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213857

    FDA
    21 Mar 2022
    Share Share
    A giant trial of COVID-19 treatments is restarting
    A giant trial of COVID-19 treatments is restarting

    06 Aug 2021

    // Kai Kupferschmidt SCIENCEMAG

    https://www.sciencemag.org/news/2021/08/giant-trial-covid-19-treatments-restarting-here-are-drugs-it-s-betting

    Kai Kupferschmidt SCIENCEMAG
    06 Aug 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.